Status:
RECRUITING
Role of Bumetanide in Treatment of Autism
Lead Sponsor:
Sherief Abd-Elsalam
Conditions:
Autism
Eligibility:
All Genders
3-12 years
Phase:
PHASE3
Brief Summary
Role of bumetanide in Autism
Detailed Description
Role of Bumetanide in Treatment of Autism spectrum disorder in children
Eligibility Criteria
Inclusion
- All patients with ASD diagnosed by CARS rating Scale⩾30.
- Age of patients range between (3-12) years.
Exclusion
- Patients with ASD associated with neurological antecedents (including epilepsies and febrile seizures), hepatic, renal dysfunction or electrocardiogram abnormalities and syndromatic children(Rett).
Key Trial Info
Start Date :
January 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2030
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT04766177
Start Date
January 1 2021
End Date
December 1 2030
Last Update
February 23 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sherief Abd-Elsalam
Tanta, Egypt